Equities research analysts forecast that Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) will report earnings of ($0.35) per share for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Tetraphase Pharmaceuticals’ earnings, with estimates ranging from ($0.40) to ($0.28). Tetraphase Pharmaceuticals reported earnings of ($0.63) per share in the same quarter last year, which suggests a positive year over year growth rate of 44.4%. The business is scheduled to announce its next earnings results on Thursday, November 1st.
According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full year earnings of ($1.40) per share for the current fiscal year, with EPS estimates ranging from ($1.82) to ($1.05). For the next financial year, analysts forecast that the business will report earnings of ($1.15) per share, with EPS estimates ranging from ($2.00) to ($0.77). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.18. Tetraphase Pharmaceuticals had a negative return on equity of 67.34% and a negative net margin of 421.64%. The business had revenue of $11.58 million for the quarter, compared to the consensus estimate of $2.23 million.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TTPH. Flagship Harbor Advisors LLC purchased a new position in Tetraphase Pharmaceuticals during the second quarter worth about $104,000. Cubist Systematic Strategies LLC lifted its position in Tetraphase Pharmaceuticals by 232.1% during the second quarter. Cubist Systematic Strategies LLC now owns 35,537 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 24,837 shares during the period. Canada Pension Plan Investment Board purchased a new position in Tetraphase Pharmaceuticals during the second quarter worth about $179,000. Dynamic Technology Lab Private Ltd lifted its position in Tetraphase Pharmaceuticals by 322.1% during the first quarter. Dynamic Technology Lab Private Ltd now owns 76,108 shares of the biopharmaceutical company’s stock worth $234,000 after buying an additional 58,079 shares during the period. Finally, Royce & Associates LP purchased a new position in Tetraphase Pharmaceuticals during the second quarter worth about $556,000. Hedge funds and other institutional investors own 40.93% of the company’s stock.
Shares of NASDAQ:TTPH opened at $2.43 on Thursday. Tetraphase Pharmaceuticals has a 52-week low of $2.05 and a 52-week high of $6.97. The firm has a market capitalization of $145.89 million, a PE ratio of -0.92 and a beta of 2.57.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Recommended Story: How to use beta for portfolio diversification
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.